-
AZD1390: Selective ATM Kinase Inhibitor
2026-08-29
AZD1390 is a selective ATM kinase inhibitor with a reported cellular IC50 of 0.78 nM. Product data support its use as a radiosensitizer for glioma and lung cancer research, while the G4 replication study provides a separate mechanistic context for ATM and ATR signaling during replication stress.
-
Marein Reverses Mitoxantrone Resistance via ABCG2
2026-08-28
The reference study identifies marein, a chalcone glucoside from Coreopsis tinctoria, as a competitive inhibitor of ABCG2-mediated drug efflux. By increasing intracellular concentrations of ABCG2 substrates, including Mitoxantrone, marein restored chemotherapy sensitivity in resistant cancer-cell models and linked this activity to interaction with the conserved F439 residue.
-
YM 58483 (BTP2) for SOCE Workflows
2026-08-28
YM 58483 (BTP2) provides a practical way to suppress sustained store-operated calcium entry while connecting calcium flux to NFAT, IL-2, and fibrotic signaling readouts. This guide adapts the compound for T cell activation assays and radiation-induced salivary-gland fibrosis models, with executable setup parameters and troubleshooting controls.
-
KU-60019: ATM Kinase Inhibitor Workflow
2026-08-27
KU-60019 is a potent, selective ATM kinase inhibitor for connecting DNA damage response experiments with glioma radiosensitization, migration assays, and metabolic vulnerability studies. This workflow-focused guide explains how to prepare, benchmark, combine, and troubleshoot the compound while keeping ovarian cancer findings appropriately hypothesis-generating.
-
BPN-19186 in sEH–Nrf2 Research Workflows
2026-08-27
BPN-19186 supports concentration-controlled studies of sEH-linked metabolite balance, Nrf2 signaling, and osteoclast differentiation. This guide translates a recent liver–bone-axis finding into practical biochemical, cellular, and troubleshooting workflows without overstating product-specific efficacy.
-
Fenipentol: Applied Workflows for Secretory Biology
2026-08-26
Fenipentol, also called 1-Phenyl-1-pentanol, supports practical investigations of hepatobiliary secretion, ESR1-linked signaling, and gastrointestinal physiology. This guide separates compound-specific evidence from findings on the related isomer 1-phenyl-2-pentanol, helping researchers design cleaner assays and avoid overinterpreting cross-compound results.
-
ABT-263 (Navitoclax) in Apoptosis Assays
2026-08-26
This scenario-driven guide explains how ABT-263 (Navitoclax), SKU A3007, can improve the design, handling, and interpretation of apoptosis and cell-viability experiments. It connects Bcl-2 family pharmacology with practical stock-preparation, assay-compatibility, resistance-analysis, and vendor-selection decisions.
-
GluN2A/GluN2B Control of TMJ Inflammatory Allodynia
2026-08-25
This reference study identifies a mechanistic link between trigeminal ganglion NMDAR subunits GluN2A and GluN2B and connexin- or pannexin-dependent communication during temporomandibular joint inflammation. Conditional knockout and satellite glial cell experiments indicate that the two subunits have distinct effects on peripheral sensitization, providing a framework for testing pathway-selective interventions in orofacial pain.
-
IR-820 (New Indocyanine Green) in Cell Assays
2026-08-25
Learn how IR-820 (New Indocyanine Green), SKU C8228, can support near-infrared imaging controls without being mistaken for a direct viability reagent. This scenario-based guide covers spectral interference, protocol design, data interpretation, storage, and practical vendor-selection criteria.
-
FITC Goat Anti-Mouse IgG: Assay Design Guide
2026-08-24
Learn how the FITC Goat Anti-Mouse IgG (H+L) Antibody supports rigorous mouse IgG detection in microscopy and flow cytometry. This guide connects secondary-antibody design with multi-omics-informed ovarian aging research and practical assay controls.
-
Triazole ALDH2 Activators in Myocardial Ischemia
2026-08-24
A 2025 ACS Medicinal Chemistry Letters study used molecular simulation and structure optimization to develop triazole-based ALDH2 activators with improved activity and water solubility. Lead compound Z17 showed strong enzyme activation and protected cardiac function in a mouse ischemia–reperfusion model, supporting further preclinical investigation while leaving pharmacokinetic and clinical questions unresolved.
-
Separating Drug Growth Inhibition from Cell Death
2026-08-23
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures in cancer drug studies. Its central contribution is a response-analysis framework that separates proliferative arrest from actual cell killing, improving interpretation of drug timing, potency, and mechanism.
-
Saracatinib: Src Signaling Across Cancer and Synapse
2026-08-22
Saracatinib (AZD0530) offers a translationally useful way to interrogate Src family kinase and Abl signaling across cancer models, while the Reelin–Apoer2–SFK literature shows why pathway context matters in synaptic biology. This article connects biochemical potency with cancer phenotypes, xenograft validation, assay design, and disciplined cross-domain interpretation.
-
Mitoxantrone Targets the ERα DBD–LBD Interface
2026-08-21
Wang et al. identify an unconventional estrogen receptor α (ERα) binding site at the interface between its DNA-binding and ligand-binding domains. Mitoxantrone binding alters receptor conformation, promotes cytoplasmic redistribution and proteasomal degradation, and suppresses therapy-resistant ERα mutants in cellular and xenograft models independently of its canonical DNA-damage activity.
-
MK-0812 as a Causal Probe in MASH
2026-08-20
MK-0812 enables targeted investigation of CCR2-dependent monocyte trafficking within the gut–liver axis of MASH. This article moves beyond descriptive inflammation studies to explain how pharmacological perturbation, compartment-specific assays, and TM6SF2 biology can be combined for stronger causal interpretation.